Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03743766 · ClinicalTrials.gov registry record · Phase 2
Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
A Phase 2 study, sponsored by John Kirkwood.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT03743766 is a Phase 2 study that has completed, run by John Kirkwood. The registered enrollment target is 42 participants.
The verdict
NCT03743766, a Phase 2 study, has completed, sponsored by John Kirkwood.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The main goal of this study is to evaluate the antitumor activity of relatlimab and nivolumab in combination in subjects with unresectable or metastatic melanoma who have not received prior treatment with immunotherapy.
Interventions
- DRUG Nivolumab
- DRUG Relatlimab
- DRUG Relatlimab + Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2019-03-29 |
| Est. Completion | 2024-07-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03743766
The ClinicalTrials.gov registry entry for NCT03743766 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is John Kirkwood, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT03743766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03743766 about?
NCT03743766 is a clinical study titled "Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting". The main goal of this study is to evaluate the antitumor activity of relatlimab and nivolumab in combination in subjects with unresectable or metastatic melanoma who have not received prior treatment with immunotherapy.
What is the current status of trial NCT03743766?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2019-03-29. Estimated completion is 2024-07-03.
What interventions are being tested in trial NCT03743766?
The interventions under investigation include: Nivolumab (DRUG), Relatlimab (DRUG), Relatlimab + Nivolumab (DRUG).
Who is sponsoring clinical trial NCT03743766?
This trial is sponsored by John Kirkwood, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.